Welcome, everyone. I'm Dr. John Whyte, the Chief Medical Officer at WebMD. Today, I want to discuss myasthenia gravis. It's a rare autoimmune neuromuscular disease that causes weakness and fatigue ...
Investor's Business Daily on MSN2d
Roivant And Immunovant Won't Seek Approval Despite Phase 3 Win. Why Shares Rallied.Immunovant and Roivant Sciences said Wednesday their rare disease drug succeeded in a final-phase study, but the duo won't seek approval.
Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Generalized myasthenia gravis (gMG) affects most patients through a handful of well-characterized neuromuscular ...
Myasthenia gravis is a neuromuscular junction disorder with a hallmark of progressive muscle weakness and frequent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback